Atherosclerosis Monitoring and Atherogenicity Reduction Study
Atherosclerosis Monitoring and Atherogenicity Reduction Study
This study was designed to estimate the effect of two-year treatment with time-released
 garlic-based drug Allicor on the progression of carotid atherosclerosis in double-blinded
 placebo-controlled randomized clinical trial.
Inclusion Criteria:

 -  Men aged 40 to 74 years

 -  Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased
 intima-media thickness 1100-2000 mcm)

 -  Arterial normotension or mild arterial hypertension (systolic blood pressure <160 mm
 Hg, diastolic blood pressure <90 mm Hg)

 -  Absence of chronic diseases demanding permanent drug administration (more than 2 month
 per year)

 Exclusion Criteria:

 -  Personal history or diagnostic of following diseases:

 1. Transient ischemic attacks

 2. Presence of chronic diseases demanding permanent drug administration (more than 2
 month per year)

 3. Condition of patients moderate to severe

 -  Indications for surgical treatment of atherosclerotic lesions localized in the
 extracranial brachiocephalic system.

 -  Individual intolerance of Allicor or appearance of side effects